enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Secukinumab - Wikipedia

   en.wikipedia.org/wiki/Secukinumab

   Secukinumab inhibits a member of the cytokine family, interleukin 17A, which is produced mainly by inflammatory T helper 17 cells. [11] IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in ...

3. Spesolimab - Wikipedia

   en.wikipedia.org/wiki/Spesolimab

   Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis (GPP). [4] It is an interleukin-36 receptor (IL-36R) antagonist. [ 4 ] [ 6 ] It is given via injection into a vein.

4. Brodalumab - Wikipedia

   en.wikipedia.org/wiki/Brodalumab

   Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. [3] [4] [5]In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.

5. Which Psoriasis Treatment is Right for You? - AOL

   www.aol.com/lifestyle/psoriasis-treatment...

   For premium support please call: 800-290-4726 more ways to reach us

6. Bristol-Myers Squibb's New Psoriasis Drug Has Echoes of Humira

   www.aol.com/news/bristol-myers-squibbs-psoriasis...

   Probably not, but its new drug candidate for plaque psoriasis BMS-986165 at least has a shot to come within the same ballpark. How did Humira get to be the best-selling drug of all time, and why ...

7. Risankizumab - Wikipedia

   en.wikipedia.org/wiki/Risankizumab

   Risankizumab was approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe plaque psoriasis in April 2019. [13] [10] [14]The FDA approved risankizumab based on evidence primarily from five clinical trials (Trial 1/NCT02684370, Trial 2/NCT02684357, Trial 3/NCT02672852, Trial 4/ NCT02694523, and Trial 5/NCT02054481) of 1606 participants with moderate to severe ...